- Home
- VRTX
as 10-23-2025 3:50pm EST
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 96.6B | IPO Year: | 1991 |
| Target Price: | $491.78 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 26 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 14.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $362.50 - $519.88 | Next Earning Date: | 11-03-2025 |
| Revenue: | $11,418,800,000 | Revenue Growth: | 10.46% |
| Revenue Growth (this year): | 10.92% | Revenue Growth (next year): | 9.55% |
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Biller Jonathan | VRTX | EVP and Chief Legal Officer | Oct 2 '25 | Sell | $404.21 | 694 | $280,521.74 | 15,653 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Business Wire
16 hours ago
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference
Insider Monkey
a day ago
Bank of America Securities Remains Bullish on Vertex Pharmaceuticals Incorporated (VRTX)
Zacks
2 days ago
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Motley Fool
5 days ago
2 Growth Stocks to Invest $1,000 in Right Now
Simply Wall St.
6 days ago
A Closer Look at Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Stability
Zacks
6 days ago
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
MT Newswires
7 days ago
Goldman Sachs Cuts Vertex Pharmaceuticals Price Target to $603 From $624, Buy Rating Kept
MT Newswires
7 days ago
Vertex Pharma Says FDA Grants Rolling Review of Povetacicept Application for IgA Nephropathy
Compare VRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.